| Literature DB >> 32712116 |
F Rubin1, J-F Vellin2, J Berkaoui3, W Al Assaf2, A Pennica3, B Girard4, P Hoarau3, P Pescatori4, M Dupre5, S Bensoussan6, P Vurpillot3, N Challut3, O Laccourreye7.
Abstract
OBJECTIVE: To analyze the impact of the first month of lockdown related to the 2020 SARS-Cov-2 epidemic on the consulting activity of private ENT physicians in Réunion Island.Entities:
Keywords: Covid-19; ENT; France; Réunion Island; SARS-CoV-2
Mesh:
Year: 2020 PMID: 32712116 PMCID: PMC7309792 DOI: 10.1016/j.anorl.2020.06.013
Source DB: PubMed Journal: Eur Ann Otorhinolaryngol Head Neck Dis ISSN: 1879-7296 Impact factor: 2.080
Fig. 1Age distribution by gender.
Main characteristics of the 693 patients consulting between March 18 and April 18, (Appendix 1).
| Age | |
| Median (range) | 44 years (9 mo–8 yrs) |
| < 18 years | 19% (135/693) |
| < 40 years | 47% (325/693) |
| > 80 years | 1% (9/693) |
| Gender (female/male) | 391/302 |
| Occupation (> 18 yrs) | |
| None | 38% (210/549) |
| Working | 45% (250/549) |
| Retired | 17% (94/549) |
Presenting symptoms (Appendix 1).
| Symptoms | (N/%) |
|---|---|
| Otologic | 390 (56.3%) |
| Pain | 214 (30.1%) |
| Hearing loss | 61 (8.8%) |
| Vertigo | 61 (8.8%) |
| Otorrhea and Otorrhagia | 31 (4.5%) |
| Tinnitus | 13 (1.9%) |
| Auricular pruritis | 6 (0.9%) |
| Peripheral facial palsy | 4 (0.6%) |
| Rhinologic | 55 (7.9%) |
| Nasal obstruction | 19 (2.7%) |
| Epistaxis | 12 (1.7%) |
| Facial/sinus pain | 9 (1.3%) |
| Rhinorrhea | 8 (1.1%) |
| Olfactive and gustatory disorder | 7 (1%) |
| Laryngologic | 16 (2.3%) |
| Dysphonic | 5 (0.7%) |
| Dyspnea | 5 (0.7%) |
| Cough | 4 (0.6%) |
| Language disorder | 2 (0.3%) |
| Cervicofacial | 77 (11.1%) |
| Cervical or pharyngeal pain or discomfort | 33 (4.7%) |
| Tumor and tumefaction | 22 (3.2%) |
| Snoring | 11 (1.6%) |
| Headache | 6 (0.9%) |
| Dysphagia | 5 (0.7%) |
| Miscellaneous | 163 (23.5%) |
| Follow-up and opinion | 160 (23%) |
| Head and neck wound and trauma | 3 (0.4%) |
Diagnoses in consultation (Appendix 1).
| Diagnoses | N/% |
|---|---|
| Otologic | 350/67.2% |
| Otitis (acute, chronic, externa, media, barotrauma, catarrh) | 241/46.2% |
| Foreign body (including wax) | 48/9.2% |
| Benign paroxysmal positional vertigo | 24/4.6% |
| Hydrops, labyrinthitis, inner ear deformity, neurinoma | 20/3.8% |
| Hearing loss (otosclerosis, presbycusis, acoustic trauma, sudden hearing loss) | 13/2.5% |
| Peripheral facial palsy | 4/0.8% |
| Rhinologic | 54/10.4% |
| Acute or chronic rhinitis or rhinosinusitis | 37/5.1% |
| Sinonasal polyposis | 9/1.7% |
| Vascular birthmark | 7/1.3% |
| Congenital anosmia | 1/0.2% |
| Laryngologic | 19/3.6% |
| Gastroesophageal reflux | 17/3.3% |
| Functional dysphonia | 2/0.4% |
| Cervicofacial | 56/10.7% |
| Acute or chronic pharyngitis, adenitis, abscess, tonsillitis | 27/5.2% |
| Tumor (benign or malignant) | 11/2.1% |
| Cyst, wound, skin infection | 10/1.9% |
| Temporo-mandibular dysfunction | 4/0.8% |
| Parotiditis, submaxillitis | 3/0.6% |
| Cochlear implant extrusion | 1/0.2% |
| Miscellaneous | 29/5.5% |
| Snoring and sleep apnea | 15/2.9% |
| Anxiety, stress | 10/1.9% |
| Cervical osteoarthritis | 2/0.4% |
| Headache, migraine | 2/0.4% |
Complementary examinations and treatments (Appendix 1).
| N (%) | |
|---|---|
| Complementary examinations | 100 (15.7%) |
| Imaging | 32 (4.6%) |
| Audiometry and/or vestibular assessment | 34 (4.9%) |
| Other medical specialist opinion | 15 (2.2%) |
| Dental surgeon opinion | 9 (1.3%) |
| Sleep polygraphy | 6 (0.9%) |
| Bacteriology sampling | 5 (0.7%) |
| Treatments | 439 (63.3%) |
| Ear drops (with or without packing) | 238 (34.3%) |
| Lavage, nasal spray, cauterization | 72 (10.3%) |
| Oral antibiotics | 56 (8.1%) |
| Oral level-1 analgesia | 55 (7.9%) |
| Oral anti-vertigo drugs | 36 (5.2%) |
| Maneuver for positional vertigo | 22 (3.2%) |
| Oral anti-gastroesophageal reflux drugs | 20 (2.9%) |
| Oral steroidal anti-inflammatory drugs | 18 (2.6%) |
| Hearing aid | 6 (0.9%) |
| Nursing care | 5 (0.7%) |
| Oral level-2/3 analgesia | 2 (0.3%) |
| Speech therapy, orthoptics, physiotherapy | 4 (0.5%) |
| Oral non-steroidal anti-inflammatory drugs | 0 (0%) |
Appendix 1 Excel database.
Fig. 2Percentage decrease in consultation turnover.
Fig. 3Cumulative progression of Cov-2-related cases and deaths in France (data at May 1, 2020: including public-sector nursing homes; N: number).
Fig. 4Cumulative progression of Cov-2-related cases and deaths in Réunion Island (data at May 1, 2020: including public-sector nursing homes; N: number).